Article
  • Docetaxel Nanocrystals Producedvia an Amorphous Precursor
  • Insil Choi, Hee-Jin Kim, Kab Sig Kim*, Yong Suk Jin*, Eun Yong Lee*, Joo Won Park*, Young-Je Kwark**, Yun Sang Lee***, Jae Hyun Jeong , and Il Won Kim

  • Department of Chemical Engineering, Soongsil University, Seoul 06978, Korea
    *Bio-Synectics, Inc., Seoul 08501, Korea
    **Department of Organic Materials and Fiber Engineering, Soongsil University, Seoul 06978, Korea
    ***Department of Physics, Soongsil University, Seoul 06978, Korea

  • 무정형 전구체를 통한 도세탁셀 나노결정의 형성
  • 최인실 ·김희진 ·김갑식* ·진용석* ·이은용* ·박주원* ·곽영제** ·이윤상*** ·정재현 ·김일원

  • 숭실대학교 화학공학과, *(주)바이오시네틱스, **숭실대학교 유기신소재·파이버공학과, ***숭실대학교 물리학과

  • Reproduction, stored in a retrieval system, or transmitted in any form of any part of this publication is permitted only by written permission from the Polymer Society of Korea.

References
  • 1. Sulkes, A.; Smyth, J.; Sessa, C.; Dirix, L. Y.; Vermorken, J. B.; Kaye, S.; Wanders, J.; Franklin, H.; LeBail, N.; Verweij, J. Docetaxel (TaxotereTM) in Advanced Gastric Cancer: Results of a Phase II Clinical Trial. Br. J. Cancer 1994, 70, 380-383.
  •  
  • 2. Fossella, F. V.; Lee, J. S.; Shin, D. M.; Calayag, M.; Huber, M.; Perez-Soler, R.; Murphy, W. K.; Lippman, S.; Benner, S.; Glisson, B. Phase II Study of Docetaxel for Advanced or Metastatic Platinum-refractory Non-small-cell Lung Cancer. J. Clin. Oncol. 1995, 13, 645-651.
  •  
  • 3. Sanofi. Taxotere®: Prescribing Information. https://products.sanofi.us/Taxotere/taxotere.html (accessed Dec 20, 2021).
  •  
  • 4. Engels, F. K.; Mathot, R. A. A.; Verweij, J. Alternative Drug Formulations of Docetaxel: A Review. Anti-Cancer Drugs 2007, 18, 95-103.
  •  
  • 5. Naguib, Y. W.; Rodriguez, B. L.; Li, X.; Hursting, S. D.; Williams III, R. O.; Cui, Z. Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and In Vivo Evaluation. Mol. Pharmaceutics 2014, 11, 1239-1249.
  •  
  • 6. Couillaud, B. M.; Espeau, P.; Mignet, N.; Corvis, Y. State of the Art of Pharmaceutical Solid Forms: From Crystal Property Issues to Nanocrystals Formulation. ChemMedChem 2019, 14, 8-23.
  •  
  • 7. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review. J. Control. Release 2000, 65, 271-284.
  •  
  • 8. Taurin, S.; Nehoff, H.; Greish, K. Anticancer Nanomedicine and Tumor Vascular Permeability; Where Is the Missing Link?. J. Control. Release 2012, 164, 265-275.
  •  
  • 9. Hollis, C. P.; Weiss, H. L.; Leggas, M.; Evers, B. M.; Gemeinhart, R. A.; Li, T. Biodistribution and Bioimaging Studies of Hybrid Paclitaxel Nanocrystals: Lessons Learned of the EPR Effect and Image-guided Drug Delivery. J. Control. Release 2013, 172, 12-21.
  •  
  • 10. Liu, F.; Park, J.-Y.; Zhang, Y.; Conwell, C.; Liu, Y.; Bathula, S. R.; Huang, L. Targeted Cancer Therapy with Novel High Drug-Loading Nanocrystals. J. Pharm. Sci. 2010, 99, 3542-3551.
  •  
  • 11. Fuhrmann, K.; Pozomska, A.; Aeberli, C.; Castagner, B.; Gauthier, M. A.; Leroux, J.-C. Modular Design of Redox-Responsive Stabilizers for Nanocrystals. ACS Nano. 2013, 7, 8243-8250.
  •  
  • 12. Pawar, V. K.; Gupta, S.; Singh, Y.; Meher, J. G.; Sharma, K.; Singh, P.; Gupta, A.; Bora, H. K.; Chaurasia, M.; Chourasia, M. K. Pluronic F-127 Stabilised Docetaxel Nanocrystals Improve Apoptosis by Mitochondrial Depolarization in Breast Cancer Cells: Pharmacokinetics and Toxicity Assessment. J. Biomed. Nanotechnol. 2015, 11, 1747-1763.
  •  
  • 13. Choi, J.; Ko, E.; Chung, H.-K.; Lee, J. H.; Ju, E. J.; Lim, H. K.; Park, I.; Kim, K.-S.; Lee, J.-H.; Son, W.-C.; Lee, J. S.; Jung, J.; Jeong, S.-Y.; Song, S. Y.; Choi, E. K. Nanoparticulated Docetaxel Exerts Enhanced Anticancer Efficacy and Overcomes Existing Limitations of Traditional Drugs. Int. J. Nanomed. 2015, 10, 6121-6132.
  •  
  • 14. Galichet, L. Y. Myristyl alcohol. In Handbook of Pharmaceutical Excipients, 6th ed.; Rowe, R. C., Sheskey, P. J., Quinn, M. E., Eds.; Pharmaceutical Press: London, 2009; pp 456-457.
  •  
  • 15. Code of Federal Regulations Title 21: Food and Drugs. https://www.ecfr.gov/cgi-bin/text-idx?SID=c1b0922b68214656303fe9df50bdf10d&mc=true&node=se21.3.172_1864&rgn=div8 (accessed Dec 20, 2021).
  •  
  • 16. Jeong, J. H.; Chan, V.; Cha, C.; Zorlutuna, P.; Dyck, C.; Hsia, K. J.; Bashir, R.; Kong, H. Living Microvascular Stamp for Patterning of Functional Neovessels; Orchestrated Control of Matrix Property and Geometry. Adv. Mater. 2012, 24, 58-63.
  •  
  • 17. Weiswald, L. B.; Bellet D.; Vorginie D. M. Spherical Cancer Models in Tumor Biology. Neoplasia 2015, 17, 1-15.
  •  
  • 18. Zaske, L.; Perrin, M.-A.; Daiguebonne, C.; Guillou, O. Docetaxel (Taxotere® Trihydrate) Forms: Crystal Structure Determination from XRPD & XRSCD Data. Mater. Sci. Forum 2004, 443-444, 411-414.
  •  
  • 19. Kim, I. W.; Robertson, R. E.; Zand, R. Selected Polymorphs of CaCO3 through Epitaxy with Inorganic Substrates Aligned with an Electric Field. Adv. Mater. 2003, 15, 709-712.
  •  
  • Polymer(Korea) 폴리머
  • Frequency : Bimonthly(odd)
    ISSN 0379-153X(Print)
    ISSN 2234-8077(Online)
    Abbr. Polym. Korea
  • 2020 Impact Factor : 0.493
  • Indexed in SCIE

This Article

  • 2022; 46(2): 275-280

    Published online Mar 25, 2022

  • 10.7317/pk.2022.46.2.275
  • Received on Dec 21, 2021
  • Revised on Dec 21, 2021
  • Accepted on Jan 7, 2022

Correspondence to

  • Jae Hyun Jeong , and Il Won Kim
  • Department of Chemical Engineering, Soongsil University, Seoul 06978, Korea

  • E-mail: nfejjh@ssu.ac.kr, iwkim@ssu.ac.kr